TYRX Release: Vanderbilt Study Shows Sharp Decline in Cardiac Device Infections With TYRX® AIGISRx® Antibacterial Envelope
12/18/2012 9:25:59 AM
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Patients at high risk for surgical site infection following Cardiac Implantable Electronic Device (CIED) implantation with TYRX, Inc.’s AIGISRx Antibacterial Envelope experienced significantly reduced risk of device infection compared to patients implanted without AIGISRx. Results of a retrospective cohort study of CIED implantations, including pacemakers and implantable defibrillators, were published online in the journal of Pacing and Clinical Electrophysiology (PACE).
comments powered by